Literature DB >> 22510023

Screening for pre-diabetes to predict future diabetes using various cut-off points for HbA(1c) and impaired fasting glucose: the Toranomon Hospital Health Management Center Study 4 (TOPICS 4).

Y Heianza1, Y Arase, K Fujihara, H Tsuji, K Saito, S D Hsieh, S Kodama, H Shimano, N Yamada, S Hara, H Sone.   

Abstract

AIM: To evaluate various screening criteria for pre-diabetes to identify which combination of impaired fasting glucose and elevated HbA(1c) values performs most effectively in predicting future diabetes in a large cohort of Japanese individuals.
METHODS: The study included 4670 men and 1571 women without diabetes (diabetes: fasting plasma glucose ≥ 7.0 mmol/l, HbA(1c) ≥ 48 mmol/mol (≥ 6.5%), or self-reported clinician-diagnosed diabetes). Pre-diabetes was diagnosed by a combination of impaired fasting glucose (fasting plasma glucose 5.6-6.9 mmol/l or 6.1-6.9 mmol/l) and elevated HbA(1c) [39-46 mmol/mol (5.7-6.4%) or 42-46 mmol/mol (6.0-6.4%)].
RESULTS: During a 5-year follow-up, 338 incident cases of diabetes occurred. The combination of HbA(1c) 39-46 mmol/mol (5.7-6.4%) and fasting plasma glucose 5.6-6.9 mmol/l yielded the highest sensitivity (86%) and generated a large population-attributable per cent risk (78%) for predicting development of diabetes. Among individuals classified as having pre-diabetes by any of the four combined criteria, 20.5-32.0% reverted to the normoglycaemic state as having neither elevated HbA(1c) nor impaired fasting glucose at the last follow-up examination. At 5.6 years after the baseline examination, however, pre-diabetic individuals who fulfilled both HbA(1c) 42-46 mmol/mol (6.0-6.4%) and fasting plasma glucose 6.1-6.9 mmol/l had a 100% cumulative risk of developing diabetes.
CONCLUSIONS: The combination of HbA(1c) 39-46 mmol/mol (5.7-6.4%) and fasting plasma glucose 5.6-6.9 mmol/l would have the best performance in reducing the likelihood of missing future cases of diabetes. Identifying pre-diabetic individuals who strictly fulfil HbA(1c) 42-46 mmol/mol (6.0-6.4%) and fasting plasma glucose 6.1-6.9 mmol/l would predict definite progression to diabetes.
© 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22510023     DOI: 10.1111/j.1464-5491.2012.03686.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  20 in total

1.  Are current diagnostic guidelines delaying early detection of dysglycemic states? Time for new approaches.

Authors:  Michael Bergman; Rachel Dankner; Jesse Roth; K M Venkat Narayan
Journal:  Endocrine       Date:  2013-01-17       Impact factor: 3.633

Review 2.  Preventing type 2 diabetes mellitus: a call for personalized intervention.

Authors:  Harry Glauber; Eddy Karnieli
Journal:  Perm J       Date:  2013

3.  Inadequacies of current approaches to prediabetes and diabetes prevention.

Authors:  Michael Bergman
Journal:  Endocrine       Date:  2013-07-24       Impact factor: 3.633

Review 4.  The Natural Course of Impaired Fasting Glucose.

Authors:  Agnieszka Święcicka-Klama; Katarzyna Połtyn-Zaradna; Andrzej Szuba; Katarzyna Zatońska
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus.

Authors:  Michael Bergman
Journal:  Endocrine       Date:  2012-11-07       Impact factor: 3.633

6.  High rates of undiagnosed and uncontrolled hypertension upon a screening campaign in rural Rwanda: a cross-sectional study.

Authors:  Evariste Ntaganda; Regine Mugeni; Emmanuel Harerimana; Gedeon Ngoga; Symaque Dusabeyezu; Francois Uwinkindi; Jean N Utumatwishima; Eugene Mutimura; Victor G Davila-Roman; Kenneth Schechtman; Aurore Nishimwe; Laurence Twizeyimana; Angela L Brown; W Todd Cade; Marcus Bushaku; Lisa de Las Fuentes; Dominic Reeds; Marc Twagirumukiza
Journal:  BMC Cardiovasc Disord       Date:  2022-04-26       Impact factor: 2.174

7.  Hair follicle characteristics as early marker of Type 2 Diabetes.

Authors:  J Jaime Miranda; Alvaro Taype-Rondan; Jose Carlos Tapia; Maria Gabriela Gastanadui-Gonzalez; Ricardo Roman-Carpio
Journal:  Med Hypotheses       Date:  2016-08-16       Impact factor: 4.411

8.  Introduction to personalized medicine in diabetes mellitus.

Authors:  Harry S Glauber; Naphtali Rishe; Eddy Karnieli
Journal:  Rambam Maimonides Med J       Date:  2014-01-21

9.  Body Composition, Metabolic Health, and Functional Impairment among Adults Treated for Abdominal and Pelvic Tumors during Childhood.

Authors:  Carmen L Wilson; Wei Liu; Wassim Chemaitilly; Carrie R Howell; Deo Kumar Srivastava; Rebecca M Howell; Melissa M Hudson; Leslie L Robison; Kirsten K Ness
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-08-13       Impact factor: 4.254

10.  Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.

Authors:  Bernd Richter; Bianca Hemmingsen; Maria-Inti Metzendorf; Yemisi Takwoingi
Journal:  Cochrane Database Syst Rev       Date:  2018-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.